Complement activation, neutrophils, and oxygen radicals in reperfusion injury

Stroke

Volumn 24, Issue 12, 1993, Pages I-41-I-47

  Lucchesi, Benedict R ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Free radicals; Myocardial infarction; Reperfusion

Indexed keywords

OXYGEN RADICAL;

ANTIGEN RECOGNITION; CELL ADHESION; CELL DAMAGE; COMPLEMENT ACTIVATION; CONFERENCE PAPER; ENDOTHELIUM CELL; HEART INFARCTION; HUMAN; INFLAMMATION; LEUKOCYTE ACTIVATION; NEUTROPHIL; PRIORITY JOURNAL; REOXYGENATION; REPERFUSION INJURY;

CELL ADHESION; CHEMOTACTIC FACTORS; COMPLEMENT; COMPLEMENT ACTIVATION; ENDOPEPTIDASES; ENDOTHELIUM, VASCULAR; HUMAN; MYOCARDIAL REPERFUSION INJURY; NEUTROPHILS; REACTIVE OXYGEN SPECIES; SUPPORT, U.S. GOV'T, P.H.S.; TERMINOLOGY;

EID: 0027492866     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: None     Document Type: Article

References (93)

1. DeWood MA, Spores J, Notske R, Mouser LT, Burroughs R, Golden MS, Lang HT. Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. N Engl J Med. 1980;303:897-902.
2. McCord JM. Free radicals and myocardial ischemia: overview and outlook. Free Radic Biol Med. 1988;4:9-14.
3. Lucchesi BR. Myocardial ischemia, reperfusion and free radical injury. Am J Cardiol. 1990;65:141-231.
4. Ambrosio G, Chiariello M. Myocardial reperfusion injury: mechanisms and management -a review.Am J Med. 1990;91:86S-88S.
5. Werns SW, Shea MJ, Lucchesi BR. Free radicals in ischemic myocardial injury. Free Radic Biol Med. 1985;1:103-110.
6. Lucchesi BR, Werns SW, Fantone JC. The role of the neutrophil and free radicals in ischemic myocardial injury. J Mol Cell Cardiol. 1989;21:1241-1251.
7. Lucchesi BR. Modulation of leukocyte-mediated myocardial reperfusion injury. Annu Rev Physiol. 1990;52:561-576.
8. Arroyo CM, Kramer JH, Leiboff RH, Mergner GW, Dickens BF, Weglicki WB. Spin trapping of oxygen and carbon-centered free radicals in ischemic canine myocardium. Free Radic Biol Med. 1987;3:313-316.
9. Kramer JH, Arroyo CM, Dickens BF, Weglicki WB. Spin trapping evidence that graded myocardial ischemia alters post-ischemic superoxide production. Free Radic Biol Med. 1987;3:153-159.
10. Zweier JL, Flaherty JT, Weisfeldt M. Direct measurement of free radical generation following reperfusion of ischemic myocardium. Proc Natl Acad Sci U S A. 1987;84:1404-1407.
11. Zweier JL, Kuppusamy P, Lutty GA. Measurement of endothelial cell free radical generation: evidence for a central mechanism of free radical injury in post ischemic tissue. Proc Natl Acad Sci USA. 1988;85:4046-4050.
12. Zweier JL. Measurement of superoxide-derived free radicals in the reperfused heart. J Biol Chem. 1988;263:1353-1357.
13. Kramer JH, Mak IT, Freedman AM, Weglicki WB. Propranolol protects against peroxidative injury and loss of viability of myocytes exposed to anoxiaJreoxygenation. J Mol Cell Cardiol. 1989;21(suppl 2):S58. Abstract.
14. Bolli R. Oxygen-derived free radicals and myocardial reperfusion injury: an overview. Cardiovasc Drugs Ther. 1991;5:249-268.
15. Eng C, Cho S, Factor SM, Kirk ES. A nonflow basis for the vulnerability of the subendocardium. J Am Coll Cardiol. 1987;9:374-379.
16. Hearse DJ, Humphrey SM, Nayler WG, Slade A, Border D. Ultra-structural damage associated with reoxygenation of the anoxic myocardium. J Mol Cell Cardiol. 1975;7:315-324.
17. Hearse DJ, Humphrey SM, Bullock GR. The oxygen paradox and the calcium paradox: two facets of the same problem? J Mol Cell Cardiol. 1978;10:641-648.
18. Kloner RA, Ellis SG, Carlson NV, Braunwald E. Coronary reper-fusion for the treatment of acute myocardial infarction: post-ischemic ventricular dysfunction. Cardiology. 1983;70:233-246.
19. Reimer KA, Jennings RB. The ‘wavefront phenomenon’ of myocardial ischemic cell death, II: transmural progression of necrosis within the framework of ischemic bed size (myocardium at risk) and collateral flow. Lab Invest. 1979;40:633-644.
20. Bush LR, Buja LM, Samowitz W, Rude RE, Wathen M, Tilton GD, Willerson JT. Recovery of left ventricular segmental function after long-term reperfusion following temporary coronary occlusion in conscious dogs: comparison of 2 and 4 hour occlusions. Circ Res. 1983;53:248-263.
21. Topol EJ, Califf RM, George BS, Kereiakes DJ, Abbottsmith CW, Candela RJ, Lee KL, Pitt B, Stack RS, O’Neill WW. A randomized trial of immediate versus delayed elective angioplasty after intravenous tissue plasminogen activator in acute myocardial infarction. N Engl J Med. 1987;317:581-588.
22. Beyersdorf F, Allen BS, Buckberg GD, Acar C, Okamoto F, Sjostrand F, Young HH, Bugyi HI. Studies on prolonged acute regional ischemia, I: evidence for preserved cellular viability after 6 hours of coronary occlusion. J Thorac Cardiovasc Surg. 1989;98:112-126.
23. Jennings RB, Ganote GB, Kloner RA, Whalen DA, Hamilton DG. Explosive swelling of myocardial cells irreversibly injured by transient ischemia. In: Fleckenstein F, Rona G, eds. Recent Advances in Studies on Cardiac Structure and Metabolism, Vol 6: Pathophysiology and Morphology of Myocardial Cell Alteration. Baltimore, Md: University Park Press; 1975:405-413.
24. Jolly SR, Kane WJ, Bailie MB, Abrams GD, Lucchesi BR. Canine myocardial reperfusion injury: its reduction by the combined administration of superoxide dismutase and catalase. Circ Res. 1984;54:277-285.
25. Werns SW, Simpson PJ, Mickelson JK, Shea MJ, Pitt B, Lucchesi BR. Sustained limitation by superoxide dismutase of canine myocardial injury due to regional ischemia followed by reperfusion. J Cardiovasc Pharmacol. 1988;11:36-44.
26. Harlan JM. Leukocyte-endothelial interactions. Blood. 1985;65:513-525.
27. Harlan JM. Neutrophil-mediated vascular injury. Acta Med Scand Suppl. 1987;715:123-129.
28. Fishbein MC, Maclean D, Maroko PR. The histopathologic evolution of myocardial infarction. Chest. 1978;73:843-849.
29. Jacob H. The role of activated complement and granulocytes in shock states and myocardial infarction. J Lab Clin Med. 1981;98:241-1251.
30. Kloner RA, Ganote LE, Jennings RB, Reimer KA. The ‘no-reflow’ phenomenon after temporary coronary occlusion in the dog. J Clin Invest. 1974;54:1496-1508.
31. Engler RL, Schmid-Schonbein GW, Pavelec RS. Leukocyte capillary plugging in myocardial ischemia and reperfusion in the dog. Am J Pathol. 1983;111:98-111.
32. Engler RL, Dahlgren MD, Peterson MA, Dobbs A, Schmid-Schonbein GW. Accumulation of polymorphonuclear leukocytes during 3-h experimental myocardial ischemia. Am J Physiol. 1986; 251:H93-H100.
33. Engler R, Covell JW. Granulocytes cause reperfusion ventricular dysfunction after 15-minute ischemia in the dog. Circ Res. 1987; 61:20-28.
34. Lucchesi BR, Mullane KM. Leukocytes and ischemia-induced myocardial injury. Ann Rev Pharmacol Toxicol. 1986;26:201-224.
35. Jolly SR, Kane WJ, Hook BG, Abrams GD, Kunkel SL, Lucchesi BR. Reduction of myocardial infarct size by neutrophil depletion: effect of duration of occlusion. Am Heart J. 1986;112:682-690.
36. Romson JL, Hook BG, Rigot VH, Schork MA, Swanson DP, Lucchesi BR. The effect of ibuprofen on accumulation of 111-indium labeled platelets and leukocytes in experimental myocardial infarction. Circulation. 1982;66:1002-1011.
37. Stocks J, Gutteridge JM, Sharp RJ, Dormandy TL. The inhibition of lipid autooxidation by human serum and its relation to serum proteins and alpha tocopherol. Clin Sci Mol Med. 1974;47:223-233.
38. Dormandy TL. Free radical oxidation and antioxidants. Lancet. 1978;1:647-650.
39. Craddock PR, Hammerschmidt DE, Moldow CF, Yamada O, Jacob HS. Granulocyte aggregation as a manifestation of membrane interactions with complement: possible role in leukocyte margination, microvascular occlusion, and endothelial damage. Semin Hematol. 1979;16:140-147.
40. Bednar M, Smith B, Pinto A, Mullane KM. Nafazatrom-induced salvage of ischemic myocardium in anesthetized dogs is mediated through inhibition of neutrophil function. Circ Res. 1985;57:131-141.
41. Mullane KM, Read N, Salmon JA, Moncada S. Role of leukocytes in acute myocardial infarction in anesthetized dogs: relationship to myocardial salvage by anti-inflammatory drugs. J Pharmacol Exp Ther. 1984;228:510-522.
42. Romson JL, Hook BG, Kunkel SL, Abrams GD, Schork MA, Lucchesi BR. Reduction of the extent of ischemic myocaidial injury by neutrophil depletion in the dog. Circulation. 1983;67:1016-1023.
43. Rossen RD, Michael LH, Kagiyama A, Savage HE, Hanson G, Reisberg MA, Moake JN, Kim SH, Self D, Weakley S. Mechanism of complement activation after coronary artery occlusion: evidence that myocardial ischemia in dogs causes release of constituents of myocardial subcellular origin that complex with human Clq in vivo. Circ Res. 1988;62:572-584.
44. Mallory GK, White PD, Salcedo-Salger J. The speed of healing myocardial infarction: a study of the pathologic anatomy in seventy-two cases. Am Heart J. 1939;18:647-671.
45. Go LO, Murry CE, Richard VJ, Weischedel GR, Jennings RB, Reimer KA. Myocardial neutrophil accumulation during reper-fusion and reversible or irreversible ischemic injury. Am J Physiol. 1988;255:H1188-H1198.
46. Babior BM. Oxidants from phagocytes: agents of defense and destruction. Blood. 1984;4:959-966.
47. Hill JH, Ward PA. The phlogistic role of C3 leukotactic fragments in myocardial infarcts in rats. J Exp Med. 1971;133:885-900.
48. Giclas PC, Pinckard RN, Olson MS. In vitro activation of complement by isolated heart subcellular membranes. J ImmunoL 1979;122:146-151.
49. Kagiyama A, Savage HE, Michael LH, Hanson G, Entman ML, Rossen RD. Molecular basis of complement activation in ischemic myocardium: identification of specific molecules of mitochondrial origin that bind human Clq and fix complement. Circ Res. 1989; 64:607-615.
50. McManus LM, Kolb WP, Crawford MH, O’Rourke RA, Grover FL, Pinckard RN. Complement localization in ischemic baboon myocardium. Lab Invest. 1983;48:436-447.
51. Pinckard RN, O’Rourke RA, Crawford MH, Grover FS, McManus LM, Ghidoni JJ, Storrs SB, Olson MS. Complement localisation and mediation of ischemic injury in baboon myocardium. J Clin Invest. 1980;66:1050-1056.
52. Rossen RD, Swain JL, Michael LH, Weakley S, Giannini E, Entman ML. Selective accumulation of the first component of complement and leukocytes in ischemic canine heart muscle: a possible initiator of an extra-myocardial mechanism of ischemic injury. Circ Res. 1985;57:119-130.
53. Perez HD, Goldstein JM. Generation of a chemotactic lipid from arachidonic acid by exposure to a superoxide generating system. FedProc. 1980;39:1170. Abstract.
54. Hartmann JR, Robinson JA, Gunnar RM. Chemotactic activity in the coronary sinus after experimental myocardial infarction: effects of pharmacologic interventions on ischemic injury. Am J CardioL 1977;40:550-555.
55. Maroko PR, Carpenter CB, Chiariello M, Fishbein MC, Radvany P, Knostman JD, Hale SL. Reduction by cobra venom factor of myocardial necrosis after coronary artery occlusion. J Clin Invest. 1978;61:661-670.
56. Engel AG, Biesecker G. Complement activation in muscle fiber necrosis: demonstration of the membrane attack complex of complement in necrotic fibers. Ann Neurol. 1982;12:289-296.
57. Mathey DG, Schafer H-J, Schofer J, Kruger W, Talakoura K, Langes K, Bhakdi S. Deposition of the terminal CSb-9 complement complex in infarcted areas of human myocardium. Circulation. 1986;74(suppl 2):372. Abstract.
58. Weisman HF, Bartow T, Leppo MK, Marsh HC Jr, Carson GR, Concino MF, Boyle MP, Roux KH, Weisfeldt ML. Soluble human complement receptor type 1: in vivo inhibitor of complement suppressing post-ischemic myocardial inflammation and necrosis. Science. 1990;249:146-151.
59. Shandelya S, Fearon D, Weisfeldt M, Zweier J. Soluble complement receptor 1 administered only at the time of reperfusion prevents post-ischemic contractile failure. Circulation. 1991; 84(suppl 2):II-83. Abstract.
60. Smith EF III, DiMartino MJ, Davis PA, Egan JW, Griswold DE, Hillegass LM, Fong K-L, Brown KS, Crysler CS. Human recombinant soluble complement receptor 1 (sCR1) therapeutically reduces myocardial ischemicJreperfusion injury. Circulation. 1991; 84(suppl 2):II-83. Abstract.
61. Homeister JW, Satoh PS, Lucchesi BR. Soluble human CR1 prevents human complement mediated damage in the rabbit perfused isolated heart. Circulation. 1991;84(suppl 2):II-83. Abstract.
62. Mullane K. Neutrophil and endothelial changes in reperfusion injury. Trends Cardiovasc Med. 1991;1:282-289.
63. Russo RG, Liotta LA, Thorgeirsson U, Brundage R, Schiffmann E. Polymorphonuclear leukocyte migration through human amnion membrane. J Cell Biol. 1981;91:459-467.
64. Sandhaus RA, McCarthy KM, Musson RA, Henson PM. Elas-tolytic proteinases of the human macrophage. Chest. 1983;83:60S. Abstract.
65. Bevilacqua MP, Pober JS, Majeau G, Cotran RS, Gimbrone MA Jr. Interleukin-1 (IL-1) induces biosynthesis and cell surface expression of procoagulant activity in human vascular endothelial cells. J Exp Med. 1984;160:618-623.
66. Bevilacqua MP, Pober JS, Wheeler ME, Cotran RS, Gimbrone MA Jr. Interleukin-1 activation of vascular endothelium: effects on procoagulant activity and leukocyte adhesion. Am J Pathol. 1985; 121:394-403.
67. Bevilaqua MP, Pober JS, Wheeler ME, Cotran RS, Gimbrone MA Jr. Interleukin-1 acts on cultured human vascular endothelium to increase the adhesion of polymorphonuclear leukocytes, monocytes and related leukocyte cell lines. J Clin Invest. 1985;769:2003-2011.
68. Harlan JM, Schwartz BR, Reidy MA, Schwartz SM, Ochs HD, Harker LA. Activated neutrophils disrupt endothelial monolayer integrity by an oxygen radical-independent mechanism. Lab Invest. 1985;52:141-150.
69. Harlan JM. Consequences of leukocyte-vessel wall interactions in inflammatory and immune reactions. Semin Thromb Hemost. 1987; 13:434-444.
70. Springer TA, Anderson DD. Functional and structural interrelationships among the Mac-1, LFA-1 family of leukocyte adhesion glycoproteins and their deficiency in a novel heritable disease. In: Springer TA, ed. Hybridoma Technology in the Biosciences and Medicine. New York, NY: Plenum Publishing Corp; 1985:191-206.
71. Gallin JI. Degranulating stimuli decrease the negative surface charge and increase the adhesiveness of human neutrophils. J Clin Invest. 1980;65:298-306.
72. Sanchez-Madrid F, Nagy JA, Robbins E, Simon P, Springer TA. A human leukocyte differentiation antigen family with distinct alpha subunits and a common beta subunit: the lymphocyte function-associated antigen (LFA-1), the C3bi complement receptor (OKM1JMac-1), and the p150,95 molecule. J Exp Med. 1983;158:1785-1803.
73. Miller LJ, Schwarting R, Springer TA. Regulated expression of the Mac-1, p 150,95 glycoprotein family during leukocyte differentiation. J Immunol. 1986;137:2891-2900.
74. Anderson DC, Miller LJ, Schmalstieg FC, Rothlein R, Springer TA. Contributions of the Mac-1 glycoprotein family to adherence-dependent granulocyte functions: structure-function assessments employing subunit-specific monoclonal antibodies. J Immunol. 1986;137:15-27.
75. Ross GD, Medof M. Membrane complement receptors specific for bound fragments of C3. Adv Immunol. 1985;37:217-267.
76. Springer TA, Thompson WS, Miller LJ, Schmalstieg FC, Anderson DC. Inherited deficiency of the Mac-1, LFA-1, p150,95 glycoprotein family and its molecular basis. J Exp Med. 1984;160:1901-1918.
77. Berger M, O’Shea J, Cross AS, Folks TM, Chused TM, Brown EJ, Frank MM. Human neutrophils increase expression of C3bi as well as C3b receptors upon activation. J Clin Invest. 1984;74:1566-1571.
78. Arnaout MA, Spits H, Terhorst C, Pitt J, Todd RF III. Deficiency of a leukocyte surface glycoprotein (LFA-1) in two patients with Mol deficiency: effects of cell activation on Mol/LFA-1 surface expression in normal and deficient leukocytes. J Clin Invest. 1984; 74:1291-1300.
79. Todd RF III, Arnaout MA, Rosin RE, Crowley CA, Peters WA, Babior BM. Subcellular localization of the large subunit of Mol (Mol-alpha, formerly gp110), a surface glycoprotein associated with neutrophil adhesion. J Clin Invest. 1984;74:1280-1290.
80. Phan SH, Gannon DE, Varani J, Ryan US, Ward PA. Xanthine oxidase activity in rat pulmonary artery endothelial cells and its alteration by activated neutrophils. Am J Pathol. 1989;134:1201-1211.
81. Friedl HP, Till GO, Ryan US, Ward PA. Mediator-induced activation of xanthine oxidase in endothelial cells. FASEB J. 1989;3:2512-2518.
82. Beller DI, Springer TA, Schreiber RD. Anti-Mac-1 selectively inhibits the mouse and human type three complement receptor. J Exp Med. 1982;156:1000-1009.
83. Wright SD, Rao PE, Wesley C, van Voorhis WC, Craigmyle LS, lida K, Talle MA, Westberg EF, Goldstein G, Silverstein SG. Identification of the C3bi receptor of human monocytes and macrophages by using monoclonal antibodies. Proc Natl Acad Sci USA. 1983;80:5699-5703.
84. Vadas MA, Gamble JR. Regulation of the adhesion of neutrophils to endothelium. Biochem Pharmacol. 1990;40:1683-1687.
85. Luscinskas FW, Bock AF, Arnaout MA, Gimbrone MA Jr. Endothelial-leukocyte adhesion molecule-i-dependent and leukocyte (CD11/CD18)-dependent mechanisms contribute to polymorphonuclear leukocyte adhesion to cytokine-activated human vascular endothelium. J Immunol. 1989; 142:2257-2263.
86. Simon RH, DeHart PD, Todd RF. Neutrophil-induced injury of rat pulmonary alveolar epithelial cells. J Clin Invest. 1986;78:1375-1386.
87. Anderson DC, Schmalsteig FC, Shearer W, Becker-Freeman K, Kohl S, Smith CW, Tosi MF, Springer T. Leukocyte LFA-1, OKM1, p150,95 deficiency syndrome: functional and biosynthetic studies of three kindreds. Fed Proc. 1985;44:2671-2677.
88. Arnaout MA, Dana N, Pitt J, Todd RF. Deficiency of two human leukocyte surface membrane glycoproteins (Mol and LFA-1). Fed Proc. 1985;44:2664-2670.
89. Boogaerts MA, Yamada O, Jacob HS, Moldow CF. Enhancement of granulocyte-endothelial cell adherence and granulocyte-induced cytotoxicity by platelet release products. Proc Natl Acad Sci USA. 1982;79:7019-7023.
90. Springer TA. The LFA-1, Mac-1 glycoprotein family and its deficiency in an inherited disease. Fed Proc. 1985;44:2660-2663.
91. Tonnesen MG, Smedly LA, Henson PM. Neutrophil-endothelial cell interactions: modulation of neutrophil adhesiveness by complement fragments CSa and C5a des arg and formyl-methionyl-leucyl-phenylalanine in vitro. J Clin Invest. 1984;74:1581-1592.
92. Berger M, Medof ME. Increased expression of complement decay-accelerating factor during activation of human neutrophils. J Clin Invest. 1987;79:214-220.
93. Simpson PJ, Todd RF III, Fantone JC, Mickelson JK, Griffin JD, Lucchesi BR. Reduction of experimental canine myocardial reper-fusion injury by a monoclonal antibody (anti-Mol, anti-CD11b) that inhibits leukocyte adhesion. J Clin Invest. 1988;81:624-629.